Farhad Ravandi
#98,778
Most Influential Person Now
Researcher
Farhad Ravandi's AcademicInfluence.com Rankings
Farhad Ravandiengineering Degrees
Engineering
#2521
World Rank
#3453
Historical Rank
Electrical Engineering
#462
World Rank
#515
Historical Rank
Farhad Ravandicomputer-science Degrees
Computer Science
#3482
World Rank
#3654
Historical Rank
Computational Linguistics
#185
World Rank
#189
Historical Rank
Machine Learning
#420
World Rank
#426
Historical Rank
Artificial Intelligence
#619
World Rank
#630
Historical Rank
Download Badge
Engineering Computer Science
Farhad Ravandi's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Farhad Ravandi Influential?
(Suggest an Edit or Addition)Farhad Ravandi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Decitabine improves patient outcomes in myelodysplastic syndromes (2006) (1434)
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (2012) (916)
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007) (675)
- Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. (2006) (474)
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System (2008) (457)
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. (2011) (392)
- Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. (2007) (386)
- Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. (2012) (374)
- Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. (2010) (367)
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (363)
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. (2013) (350)
- Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. (2007) (340)
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. (2010) (328)
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. (2010) (322)
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. (2019) (319)
- A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies (2006) (313)
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies (2018) (304)
- A prognostic score for patients with lower risk myelodysplastic syndrome (2008) (301)
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. (2011) (300)
- Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. (2010) (297)
- Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. (2009) (290)
- Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies (2006) (288)
- Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. (2011) (274)
- Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (267)
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia (2013) (261)
- Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. (2017) (253)
- The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. (2007) (236)
- Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. (2010) (232)
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy (2010) (228)
- Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. (2016) (224)
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML (2015) (222)
- Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. (2006) (218)
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. (2015) (216)
- An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. (2012) (215)
- A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. (2008) (204)
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. (2012) (203)
- Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. (2013) (189)
- Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. (2010) (188)
- Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. (2017) (188)
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias (2011) (187)
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies (2008) (181)
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. (2012) (181)
- TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes (2016) (178)
- The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (2018) (177)
- Acute myeloid leukemia: current progress and future directions (2021) (174)
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. (2015) (171)
- Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. (2007) (171)
- Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. (2016) (169)
- Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. (2017) (167)
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (2015) (165)
- Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. (2012) (165)
- Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. (2009) (164)
- Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring (2014) (162)
- Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia (2015) (158)
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. (2020) (158)
- Pre-leukemic clonal hematopoiesis and the risk of therapy-related myeloid neoplasms: a case-control study (2016) (157)
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia (2018) (156)
- Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics (2020) (156)
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. (2018) (155)
- The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-α in BCR-ABL-expressing Cells* (2001) (154)
- Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. (2006) (153)
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. (2010) (150)
- Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. (2011) (149)
- Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration (2012) (148)
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson (2014) (147)
- Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. (2012) (147)
- Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis (2016) (141)
- Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. (2007) (141)
- Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. (2020) (139)
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome (2007) (139)
- Immune defects in patients with chronic lymphocytic leukemia (2006) (138)
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. (2020) (138)
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. (2018) (137)
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. (2018) (137)
- Outcome of adults with acute lymphocytic leukemia after second salvage therapy (2008) (135)
- Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines (2013) (135)
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. (2020) (134)
- Monoclonal antibodies in acute lymphoblastic leukemia. (2015) (133)
- Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome (2015) (132)
- Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2014) (132)
- Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. (2017) (130)
- Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. (2013) (128)
- Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide* (2002) (127)
- Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia (2015) (124)
- US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. (2016) (122)
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. (2020) (122)
- Eradication of minimal residual disease in hairy cell leukemia. (2006) (121)
- Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant. (2006) (121)
- Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia (2007) (120)
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy (2009) (119)
- Evaluating measurable residual disease in acute myeloid leukemia. (2018) (119)
- Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (2011) (118)
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. (2017) (118)
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. (2015) (116)
- Secondary mutations as mediators of resistance to targeted therapy in leukemia. (2015) (114)
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial (2017) (114)
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis (2008) (113)
- Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma (2004) (113)
- A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. (2018) (113)
- Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome (2007) (112)
- 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
- Decitabine in the treatment of myelodysplastic syndromes (2010) (110)
- Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration (2010) (109)
- Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations (2014) (109)
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. (2016) (109)
- High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. (2008) (108)
- Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. (2008) (107)
- Gemtuzumab ozogamicin: time to resurrect? (2012) (106)
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia (2008) (106)
- Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients (2017) (104)
- Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. (2013) (103)
- Activity of alemtuzumab in patients with CD52‐positive acute leukemia (2006) (102)
- Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. (2010) (101)
- Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. (2011) (99)
- Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. (2009) (99)
- Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations (2014) (99)
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (2019) (98)
- Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia (2016) (96)
- Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. (2008) (95)
- The JAK-STAT pathway: a therapeutic target in hematological malignancies. (2006) (95)
- Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. (2018) (95)
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine (2008) (95)
- Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities (2009) (93)
- Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure (2007) (93)
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. (2008) (93)
- Frontline treatment of acute myeloid leukemia in adults. (2017) (92)
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia (2021) (91)
- Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. (2011) (91)
- Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. (2011) (89)
- The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission (2019) (88)
- Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen (2016) (88)
- Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. (2016) (88)
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms (2019) (88)
- Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. (2020) (87)
- Acute myeloid leukemia, version 2.2013. (2013) (86)
- Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia (2019) (86)
- Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high‐risk myelodysplastic syndrome (2010) (86)
- Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options (2012) (86)
- Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes (2017) (85)
- Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. (2006) (84)
- Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. (2011) (84)
- Progress in the treatment of acute myeloid leukemia (2007) (82)
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage (2018) (82)
- Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations (2014) (82)
- Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes (2016) (81)
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia (2015) (80)
- Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. (2015) (80)
- FLT3 inhibitors in the treatment of acute myeloid leukemia (2011) (80)
- Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia (2018) (79)
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia (2014) (78)
- Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia (2006) (78)
- A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia (2011) (78)
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. (2019) (78)
- IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression (2015) (78)
- FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia (2013) (77)
- Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts (2018) (77)
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial (2014) (77)
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy (2012) (76)
- Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. (2017) (76)
- Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome (2009) (75)
- 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party (2021) (75)
- Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. (2019) (72)
- Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2020) (72)
- Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. (2019) (72)
- Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution (2009) (72)
- Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells* (2004) (72)
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia (2017) (71)
- Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). (2007) (71)
- Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. (2010) (71)
- A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. (2015) (70)
- Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions (2020) (69)
- NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. (2019) (69)
- Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. (2012) (69)
- Acute promyelocytic leukemia: A population‐based study on incidence and survival in the United States, 1975‐2008 (2012) (69)
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. (2015) (69)
- Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. (2011) (68)
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies (2013) (68)
- Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance (1999) (68)
- Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. (2006) (68)
- Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. (2011) (68)
- Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors (2017) (68)
- Survival is poorer in patients with secondary core‐binding factor acute myelogenous leukemia compared with de novo core‐binding factor leukemia (2009) (68)
- Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia (2009) (67)
- Treatment of core‐binding‐factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony‐stimulating factor results in improved event‐free survival (2008) (66)
- Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. (2020) (66)
- Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. (2009) (65)
- Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. (2011) (65)
- Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. (2015) (65)
- Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression (2018) (65)
- Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. (2006) (65)
- TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. (2020) (64)
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome (2016) (64)
- Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes (2018) (64)
- NCCN Clinical Practice Guidelines Acute myeloid leukemia. (2012) (63)
- Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia (2009) (63)
- Treating Leukemia in the Time of COVID-19 (2020) (62)
- Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. (2020) (62)
- The bruton tyrosine kinase inhibitor ibrutinib (PCI‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach (2014) (62)
- Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial (2016) (62)
- Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis (2015) (62)
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia (2021) (61)
- Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents (2014) (61)
- Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) (2016) (61)
- Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma (2018) (61)
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. (2016) (60)
- Therapy-related acute promyelocytic leukemia (2011) (60)
- Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia (2019) (59)
- Biphenotypic acute leukaemia: a case series (2007) (59)
- Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases (2000) (59)
- Clofarabine plus low‐dose cytarabine followed by clofarabine plus low‐dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients (2012) (59)
- A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. (2014) (58)
- Clofarabine combinations as acute myeloid leukemia salvage therapy (2008) (58)
- Late relapses in acute myeloid leukemia: analysis of characteristics and outcome (2010) (57)
- Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. (2019) (57)
- Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. (2009) (56)
- Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis (2019) (56)
- Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. (2013) (56)
- Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML (2013) (55)
- Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. (2017) (54)
- Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis (2015) (54)
- Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia (2017) (54)
- A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (2018) (54)
- Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors (2015) (53)
- Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. (2019) (53)
- Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia (2014) (53)
- CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. (2002) (53)
- New drugs in acute myeloid leukemia. (2016) (53)
- Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. (2017) (53)
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia (2014) (52)
- Acute Myeloid Leukemia (2017) (52)
- A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS) (2018) (52)
- Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. (2009) (52)
- Is acute myeloid leukemia a liquid tumor? (2013) (52)
- Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? (2019) (52)
- Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). (2020) (52)
- Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax (2021) (51)
- Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. (2011) (51)
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2015) (51)
- Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms (2018) (51)
- A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission (2012) (51)
- Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience (2009) (50)
- Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease (2017) (50)
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. (2015) (50)
- A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. (2018) (50)
- Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis (2015) (50)
- Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. (2012) (50)
- A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). (2015) (49)
- Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients (2012) (49)
- Expression of apoptosis proteins in chronic myelogenous leukemia (2001) (49)
- Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia (2015) (49)
- Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. (2015) (49)
- Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin (2012) (49)
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia (2013) (48)
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. (2020) (48)
- Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high‐dose cytarabine‐based induction chemotherapy (2014) (48)
- Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. (2014) (48)
- Potential role of sorafenib in the treatment of acute myeloid leukemia (2008) (48)
- Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome (2009) (48)
- The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). (2006) (48)
- Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. (2015) (48)
- Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. (2011) (48)
- Therapeutic implications of menin inhibition in acute leukemias (2021) (47)
- The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities (2009) (47)
- Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies (2014) (47)
- Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation (2013) (47)
- Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia (2018) (47)
- Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia (2014) (47)
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach (2021) (47)
- Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia (2011) (46)
- Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. (2020) (46)
- The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience (2014) (46)
- A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase (2007) (46)
- Regimen-related toxicity after fludarabine–melphalan conditioning: a prospective study of 31 patients with hematologic malignancies (2003) (46)
- Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors (2015) (46)
- More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. (2017) (45)
- Progress in acute myeloid leukemia. (2015) (45)
- Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. (2021) (45)
- Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma (2006) (45)
- Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. (2017) (44)
- Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells (2013) (44)
- Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation (2017) (44)
- Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach (2017) (44)
- Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. (2015) (44)
- The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia (2012) (44)
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias (2020) (44)
- Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes (2018) (43)
- A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure (2013) (43)
- MYC protein expression is an important prognostic factor in acute myeloid leukemia (2019) (43)
- Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study (2018) (43)
- Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. (2015) (43)
- Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia (2012) (43)
- Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2016) (42)
- Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML (2021) (42)
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 (2021) (42)
- Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study (2001) (42)
- Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia (2008) (41)
- Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (2019) (41)
- Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality (2020) (41)
- Long‐term follow‐up of a phase I study of high‐dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias (2003) (41)
- A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia (2011) (41)
- Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML) (2016) (41)
- Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. (2003) (40)
- Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. (2012) (40)
- Acute promyelocytic leukemia current treatment algorithms (2021) (39)
- Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias (2017) (39)
- Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS (2016) (39)
- FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm (2021) (39)
- Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia (2015) (39)
- A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia (2010) (39)
- T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. (2009) (39)
- Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience (2014) (39)
- A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome (2011) (39)
- T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. (2007) (38)
- Immunotherapy in Acute Myeloid Leukemia: Where We Stand (2021) (38)
- Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS (2012) (38)
- Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front‐line Treatment of Newly Diagnosed Philadelphia‐positive Acute Lymphoblastic Leukemia (2018) (38)
- Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia (2005) (38)
- Relapsed acute myeloid leukemia: why is there no standard of care? (2013) (38)
- Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. (2015) (37)
- A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. (2014) (37)
- A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia (2017) (36)
- Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (2018) (36)
- Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome (2012) (36)
- Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors (2018) (36)
- BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. (2008) (36)
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. (2013) (36)
- Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia (2010) (36)
- Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience (2015) (35)
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study (2019) (35)
- Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) (2017) (35)
- Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody (2015) (35)
- Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. (2012) (35)
- Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. (2010) (35)
- Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents (2017) (35)
- Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia (2016) (35)
- Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor (2017) (35)
- Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) (2016) (35)
- Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse (2018) (35)
- Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy (2020) (34)
- Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody (2010) (34)
- Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia (2017) (34)
- Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia (2020) (34)
- Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. (2014) (34)
- Outcome of therapy‐related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy (2011) (34)
- Safety and clinical activity of 5‐aza‐2′‐deoxycytidine (decitabine) with or without Hyper‐CVAD in relapsed/refractory acute lymphocytic leukaemia (2014) (34)
- Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse (2009) (34)
- How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. (2019) (34)
- Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study (2020) (34)
- Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. (2005) (34)
- Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia (2008) (34)
- Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. (2018) (33)
- Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL) (2018) (33)
- Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes (2010) (33)
- Alemtuzumab in CLL and Other Lymphoid Neoplasms (2006) (33)
- Potential cure of acute myeloid leukemia (2007) (33)
- Acute myeloid leukemia in the elderly: do we know who should be treated and how? (2014) (33)
- Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML) (2016) (33)
- Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. (2020) (33)
- Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults (2018) (33)
- Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission (2017) (32)
- Acute erythroleukemia: diagnosis and management (2010) (32)
- Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. (2016) (32)
- Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. (2006) (32)
- How I manage patients with hairy cell leukaemia (2017) (32)
- Forodesine: review of preclinical and clinical data. (2010) (32)
- New agents in acute myeloid leukemia and other myeloid disorders (2004) (32)
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. (2020) (32)
- Primary refractory acute myeloid leukaemia – in search of better definitions and therapies (2011) (32)
- Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy. (2011) (32)
- Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. (2017) (32)
- Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases. (2010) (32)
- First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) (2013) (32)
- Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study (2016) (31)
- Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib (2019) (31)
- Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. (2018) (31)
- Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. (2013) (31)
- Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. (2013) (31)
- Acute Myeloid Leukemia: Past, Present, and Prospects for the Future. (2016) (31)
- Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐trans retinoic acid and arsenic trioxide (2015) (31)
- Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphoma (2017) (30)
- Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia. (2021) (30)
- Elacytarabine has single‐agent activity in patients with advanced acute myeloid leukaemia (2012) (30)
- Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2019) (30)
- Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. (2015) (30)
- Role of cytokines in the treatment of acute leukemias: a review (2006) (30)
- A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study (2021) (30)
- Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. (2001) (30)
- Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations (2021) (30)
- How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? (2019) (30)
- Mature T‐cell leukemias (2005) (30)
- Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. (2017) (29)
- Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2019) (29)
- T-cell prolymphocytic leukemia: a single-institution experience. (2005) (29)
- A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia (2020) (29)
- Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia (2019) (29)
- A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML) (2015) (29)
- Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. (2020) (29)
- Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse (2014) (29)
- Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. (2009) (29)
- The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia (2015) (29)
- Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (2016) (29)
- Prognostic impact of RAS mutations in patients with myelodysplastic syndrome (2013) (29)
- Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities (2010) (29)
- Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia (2019) (29)
- Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics (2014) (29)
- Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report). (2006) (28)
- Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia (2017) (28)
- Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia (2017) (28)
- Update on the Biology and Treatment Options for Hairy Cell Leukemia (2014) (28)
- Copy number alterations detected as clonal hematopoiesis of indeterminate potential. (2017) (28)
- Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high‐dose cytarabine chemotherapy (2009) (28)
- Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months (2013) (28)
- Relapse and death during first remission in acute myeloid leukemia (2008) (28)
- REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia (2014) (28)
- Results of a phase I/II study of the combination of 5-aza-2’-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome (2005) (28)
- A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia (2015) (27)
- Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R (2018) (27)
- Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? (2017) (27)
- MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. (2015) (27)
- Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. (2013) (27)
- Predicting survival of patients with hypocellular myelodysplastic syndrome (2012) (27)
- A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome (2016) (27)
- Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine (2021) (27)
- Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. (2013) (27)
- Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors (2009) (27)
- Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. (2008) (27)
- Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. (2011) (27)
- Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia (2014) (27)
- Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. (2015) (27)
- Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (2018) (27)
- Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation. (2017) (27)
- Prediction model for mortality after intracranial hemorrhage in patients with leukemia (2011) (27)
- Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. (2020) (27)
- Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. (2017) (27)
- CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY (2002) (27)
- A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher‐risk myelodysplastic syndrome (2012) (26)
- Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome (2015) (26)
- A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2016) (26)
- Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents (2017) (26)
- Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors (2020) (26)
- Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse (2006) (26)
- Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 (2021) (26)
- Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase (2017) (26)
- A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. (2012) (26)
- Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts (2015) (26)
- Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML) (2016) (26)
- Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high‐risk myelodysplastic syndrome (2009) (26)
- Modeling interactions between leukemia‐specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core‐binding factor leukemias (2009) (26)
- Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. (2005) (25)
- Clinical activity of Crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia (AML). (2014) (25)
- Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience (2018) (25)
- Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). (2007) (25)
- Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL) (2015) (25)
- Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. (2015) (25)
- Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy (2021) (25)
- Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. (2007) (25)
- Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML (2016) (25)
- Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR) (2014) (24)
- Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors (2019) (24)
- A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia (2019) (24)
- Very long‐term follow‐up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy (2012) (24)
- Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens (2018) (24)
- Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. (2010) (24)
- Philadelphia chromosome-positive acute lymphoblastic leukemia. (2009) (24)
- Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome (2012) (24)
- Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML) (2013) (24)
- Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time? (2012) (24)
- Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). (2016) (24)
- Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) (2019) (24)
- Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial (2016) (24)
- Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications. (2011) (23)
- Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL) (2013) (23)
- Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide (2015) (23)
- SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML (2015) (23)
- Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia (2018) (23)
- Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. (2020) (22)
- TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia (2022) (22)
- Influence of IDH on FLT3-ITD status in newly diagnosed AML (2017) (22)
- Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL) (2013) (22)
- The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia (2020) (22)
- Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML. (2015) (22)
- A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia (2021) (22)
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials (2017) (22)
- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. (2018) (22)
- Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. (2006) (22)
- Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia (2006) (22)
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3‐ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: Abstract: AML‐014 (2017) (22)
- Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. (2013) (22)
- The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival (2019) (22)
- The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia (2013) (22)
- Arsenic trioxide: expanding roles for an ancient drug? (2004) (22)
- Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML). (2006) (22)
- Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. (2007) (21)
- Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2019) (21)
- Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations (2018) (21)
- Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia (2021) (21)
- A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. (2021) (21)
- Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase (2018) (21)
- Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. (2013) (21)
- Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) (2008) (21)
- Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia (2015) (21)
- Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade (2015) (20)
- Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies (2012) (20)
- Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML (2012) (20)
- A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors (2018) (20)
- Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia (2020) (20)
- Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida) (2019) (20)
- Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders (2019) (20)
- Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy (2011) (20)
- Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia (2021) (20)
- Infections associated with purine analogs and monoclonal antibodies. (2005) (20)
- Imatinib front‐line therapy is safe and effective in patients with chronic myelogenous leukemia with pre‐existing liver and/or renal dysfunction (2010) (20)
- Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study (2018) (20)
- Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. (2013) (20)
- Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors (2021) (20)
- Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS) (2008) (20)
- Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL) (2012) (20)
- Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000 (2018) (20)
- Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD (2013) (20)
- The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia (2015) (20)
- Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors (2019) (20)
- TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation (2013) (19)
- Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial (2018) (19)
- Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML (2020) (19)
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements (2021) (19)
- Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL. (2014) (19)
- Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). (2009) (19)
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia (2021) (19)
- Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms (2022) (19)
- Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (2011) (19)
- Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome (2018) (19)
- Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. (2010) (18)
- Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. (2018) (18)
- Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. (2012) (18)
- Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia (2018) (18)
- Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. (2020) (18)
- Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) (2011) (18)
- Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. (2016) (18)
- Therapy‐related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens (2009) (18)
- A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML (2019) (18)
- Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. (2022) (18)
- A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials (2017) (18)
- Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission (2010) (18)
- Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2021) (18)
- A phase I study of recombinant interferon-beta in patients with advanced malignant disease. (1999) (18)
- Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) (2008) (18)
- Novel therapeutic options for relapsed hairy cell leukemia (2015) (18)
- A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2018) (18)
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy (2022) (18)
- Anthracycline dose intensification in adult acute lymphoblastic leukemia (2010) (18)
- Clinical characteristics of Philadelphia positive T‐cell lymphoid leukemias—(De novo and blast phase CML) (2017) (17)
- Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL). (2010) (17)
- Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. (2011) (17)
- Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia. (2016) (17)
- Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results (2016) (17)
- Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. (2022) (17)
- Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB) (2008) (17)
- Impact of numerical variation in FMS‐like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia (2012) (17)
- Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study (2020) (17)
- Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib (2011) (17)
- Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia (2019) (17)
- Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor (2015) (17)
- Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study (2018) (16)
- Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization (2014) (16)
- Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes (2016) (16)
- Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia (2021) (16)
- Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199 (2017) (16)
- A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia (2018) (16)
- Chemo-immunotherapy for hairy cell leukemia (2011) (16)
- Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia (2021) (16)
- Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation (2019) (16)
- Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (2021) (16)
- Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. (2021) (16)
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. (2016) (16)
- SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML (2012) (16)
- A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome (2021) (16)
- Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia (2018) (16)
- Update of a Phase I Study of Sorafenib in Patients with Refractory/Relapsed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. (2007) (16)
- Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine (2010) (16)
- Response kinetics and factors predicting survival in core-binding factor leukemia (2018) (16)
- Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) (2014) (16)
- Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial (2019) (16)
- Hairy cell leukemia and COVID-19 adaptation of treatment guidelines (2021) (16)
- Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms (2016) (16)
- Long‐term results of frontline dasatinib in chronic myeloid leukemia (2020) (16)
- Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia. (2021) (16)
- Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure. (2008) (15)
- Decitabine improves response rate and prolongs progression‐free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO‐016 trial (2018) (15)
- Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia. (2004) (15)
- CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial (2020) (15)
- Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL). (2007) (15)
- Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine. (2013) (15)
- Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia (2016) (15)
- Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML (2022) (15)
- Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML (2017) (15)
- Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA) (2012) (15)
- Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia (2019) (15)
- Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. (2017) (15)
- Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. (2012) (15)
- Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment (2010) (15)
- NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemia (2019) (15)
- Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. (2021) (15)
- Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial (2020) (15)
- Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine (2020) (15)
- Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia (2020) (15)
- An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia (2021) (15)
- Decitabine in older adults with acute myeloid leukemia: why was the dream broken? (2013) (15)
- Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients (2020) (15)
- The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? (2011) (15)
- A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. (2013) (14)
- Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2015) (14)
- Impact of TKIs post–allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive ALL (2020) (14)
- Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial (2017) (14)
- Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies (2015) (14)
- Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). (2005) (14)
- Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). (2007) (14)
- Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. (2014) (14)
- Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome (2019) (14)
- Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia (2017) (14)
- Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial. (2016) (14)
- TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens (2017) (14)
- Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. (2013) (14)
- Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (2019) (14)
- Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. (2021) (14)
- Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60 (2015) (14)
- Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. (2013) (14)
- Myeloid sarcoma. (2020) (14)
- Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions (2015) (14)
- A potential role of ruxolitinib in leukemia (2011) (14)
- Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. (2014) (14)
- The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets (2011) (14)
- Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia (2016) (14)
- Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL (2020) (14)
- Factors associated with risk of central nervous system relapse in patients with non‐core binding factor acute myeloid leukemia (2017) (14)
- Clinical activity of arsenic trioxide in Burkitt-like lymphoma (2003) (14)
- Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome (2017) (13)
- A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase (2016) (13)
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia (2015) (13)
- Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2019) (13)
- Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia (2012) (13)
- Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients (2011) (13)
- Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) (2008) (13)
- Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations (2013) (13)
- Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) (2018) (13)
- Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications (2021) (13)
- Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (2020) (13)
- Impact of frontline treatment approach on outcomes of myeloid blast phase CML (2021) (13)
- Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib (2021) (13)
- Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? (2016) (13)
- A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) (2020) (13)
- FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist (2018) (13)
- Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (2011) (13)
- Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study (2018) (13)
- Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia (2021) (13)
- FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations (2011) (13)
- Clinical outcomes in adult patients with aplastic anemia: A single institution experience (2017) (13)
- Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. (2012) (13)
- Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes (2021) (13)
- Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States (2019) (13)
- Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation (2021) (13)
- Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure. (2009) (13)
- Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. (2020) (13)
- Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. (2013) (12)
- The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes (2020) (12)
- Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study (2021) (12)
- Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. (2014) (12)
- Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy (2016) (12)
- Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). (2005) (12)
- Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia (2019) (12)
- Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis (2020) (12)
- Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL) (2015) (12)
- Activity of venetoclax-based therapy in chronic myelomonocytic leukemia (2021) (12)
- A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies. (2007) (12)
- Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. (2016) (12)
- Phase II Study of Forodesine, a PNP Inhibitor, in Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia. (2006) (12)
- High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse (2022) (12)
- A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia (2018) (12)
- Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia (2021) (12)
- Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation (2018) (12)
- Acute Promyelocytic Leukemia: A Perspective. (2017) (12)
- Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2019) (12)
- Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia (2019) (12)
- Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study (2020) (12)
- Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML, (2011) (12)
- Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients (2019) (12)
- Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles (2017) (12)
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials (2023) (11)
- FLT3 inhibitor quizartinib (AC220) (2019) (11)
- Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). (2009) (11)
- Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. (2008) (11)
- Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. (2022) (11)
- Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). (2007) (11)
- Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors (2022) (11)
- Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. (2013) (11)
- Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents (2017) (11)
- Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse (2019) (11)
- Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years (2008) (11)
- Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL (2012) (11)
- Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB). (2009) (11)
- Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib. (2007) (11)
- Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. (2015) (11)
- Activity of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL). (2012) (11)
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. (2021) (11)
- Monoclonal antibody therapy for hairy cell leukemia. (2006) (11)
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (2022) (11)
- Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors (2021) (11)
- Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis. (2004) (11)
- A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results. (2018) (11)
- Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting (2016) (11)
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics (2016) (11)
- Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype (2020) (11)
- Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). (2008) (11)
- Results of a Phase II Trial of Dasatinib As Frontline Therapy for Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) (2011) (11)
- Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy. (2021) (10)
- Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series (2020) (10)
- Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP). (2006) (10)
- Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome. (2007) (10)
- Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. (2019) (10)
- Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies (2003) (10)
- Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? (2016) (10)
- Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) (2018) (10)
- Novel Agents in Acute Myeloid Leukemia (2006) (10)
- Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience (2021) (10)
- Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity (2012) (10)
- Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy (2018) (10)
- Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations (2018) (10)
- Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML) (2015) (10)
- Chemoimmunotherapy for hairy cell leukemia. (2015) (10)
- Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years (2020) (10)
- FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status. (2009) (10)
- Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR–ABL kinase domain mutations (2018) (10)
- Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. (2022) (10)
- Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy. (2006) (10)
- Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy (2011) (10)
- Molecular identification of CBFβ-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses – a rare occurrence (2003) (10)
- Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML) (2010) (10)
- Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). (2011) (10)
- Outcomes of Patients With Relapsed Core Binding Factor‐Positive Acute Myeloid Leukemia (2018) (10)
- Purine analogues in advanced T-cell lymphoid malignancies. (2006) (9)
- Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia (2012) (9)
- Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (2022) (9)
- Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL). (2014) (9)
- Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia (2010) (9)
- Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia. (2017) (9)
- Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML). (2009) (9)
- Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. (2011) (9)
- Acute myeloid leukemia. (2008) (9)
- Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. (2021) (9)
- Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. (2013) (9)
- The Search for Better Prognostic Models in Myelodysplastic Syndromes (2011) (9)
- Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin (2020) (9)
- The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes (2015) (9)
- Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. (2013) (9)
- Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. (2010) (9)
- A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML. (2009) (9)
- A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia (2008) (9)
- Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). (2021) (9)
- Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients (2020) (9)
- Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis (2021) (9)
- Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML) (2020) (9)
- Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience (2018) (9)
- Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. (2022) (9)
- Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study. (2009) (9)
- Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS) (2010) (9)
- Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. (2022) (9)
- Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). (2007) (9)
- Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia (2020) (9)
- Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2019) (9)
- A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (2010) (9)
- Ocular extramedullary myeloid leukaemia (2018) (9)
- Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. (2013) (8)
- A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia (2018) (8)
- Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations (2020) (8)
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (2022) (8)
- Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens (2017) (8)
- Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia (2015) (8)
- Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. (2003) (8)
- Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults (2015) (8)
- Clinical and molecular characterization of myeloid sarcoma without medullary leukemia (2021) (8)
- Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen. (2007) (8)
- Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma. (2009) (8)
- Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS. (2020) (8)
- Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity (2017) (8)
- Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study (2018) (8)
- Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial (2016) (8)
- Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant (2015) (8)
- Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. (2011) (8)
- First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL) (2020) (8)
- The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?. (2008) (8)
- Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications (2008) (8)
- AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. (2022) (8)
- Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. (2022) (8)
- 5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs) (2015) (8)
- Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia (2018) (8)
- Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). (2007) (8)
- Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (2020) (8)
- Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). (2005) (8)
- Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study (2021) (8)
- Prediction of survival with intensive chemotherapy in acute myeloid leukemia (2022) (8)
- Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM). (2006) (8)
- Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML, (2011) (8)
- A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. (2009) (8)
- Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia (2011) (8)
- Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies (2011) (8)
- Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia (2021) (7)
- Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure (2012) (7)
- Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome (2018) (7)
- CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia (2016) (7)
- Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML) (2015) (7)
- The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review (2016) (7)
- Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia (2020) (7)
- Translocation t(17;18)(q10;q10) (2001) (7)
- Infections in chronic leukemias and other hematological malignancies (2003) (7)
- Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL) (2011) (7)
- Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance (2021) (7)
- CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial (2020) (7)
- Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) (2008) (7)
- Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. (2015) (7)
- Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia (2012) (7)
- Dasatinib, an immunomodulator? (2010) (7)
- A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia (2011) (7)
- Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias (2018) (7)
- Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (2018) (7)
- A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs). (2006) (7)
- Forodesine (FodosineTM), a PNP Inhibitor Active in Relapsed or Refractory T-Cell Leukemia Patients (Phase II Study). (2005) (7)
- Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML). (2021) (7)
- Acute Myeloid Leukemia , Version 3 . 2019 (2019) (7)
- Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia (2017) (7)
- Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors (2011) (7)
- Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). (2020) (7)
- Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial (2021) (7)
- Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy. (2007) (7)
- Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib (2022) (7)
- Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. (2011) (7)
- CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count (2016) (7)
- Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies (2012) (7)
- Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (7)
- Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy (2009) (7)
- Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP). (2020) (7)
- Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin. (2008) (7)
- Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) (2016) (7)
- Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). (2009) (7)
- Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma (2020) (7)
- Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia (2014) (6)
- Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen (2012) (6)
- Is it time to routinely incorporate MRD into practice? (2018) (6)
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response (2020) (6)
- The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis (2020) (6)
- Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS (2022) (6)
- Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2016) (6)
- Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant (2020) (6)
- Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML). (2008) (6)
- Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) (2015) (6)
- Abstract CT307: Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) (2014) (6)
- Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation (2016) (6)
- Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial (2021) (6)
- A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS (2013) (6)
- The clinical impact of time to response in de novo accelerated‐phase chronic myeloid leukemia (2020) (6)
- Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD (2022) (6)
- Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) (2019) (6)
- Phase I study of s-trans, trans-farnesylthiosalicylic acid (FTS), a novel oral Ras inhibitor, in patients with refractory hematologic malignancies (2007) (6)
- Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms (2017) (6)
- Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. (2018) (6)
- Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrom (2011) (6)
- Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Adapted Augmented Berlin-Frankfurt-Munster (ABFM) Therapy (2008) (6)
- Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes (2020) (6)
- Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML (2021) (6)
- A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (2013) (6)
- Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. (2019) (6)
- Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). (2013) (6)
- Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality (2020) (6)
- Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. (2009) (6)
- Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission (2015) (6)
- Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. (2007) (6)
- Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. (2011) (6)
- Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS (2010) (6)
- Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. (2021) (6)
- Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. (2011) (6)
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia (2019) (6)
- Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. (2022) (6)
- Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center. (2008) (6)
- Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib. (2009) (6)
- The cure of leukemia through the optimist's prism (2021) (6)
- Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2016) (6)
- Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. (2020) (6)
- Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways. (2008) (6)
- The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. (2019) (6)
- Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL) (2019) (6)
- Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high‐risk myelodysplastic syndrome (2007) (6)
- Time to abandon traditional chemotherapy for acute promyelocytic leukaemia? (2015) (6)
- Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure (2022) (6)
- A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities (2014) (6)
- Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial (2020) (6)
- A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML). (2006) (6)
- Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy (2011) (5)
- Abstract 2779: A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome (2016) (5)
- Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) ≥ 60 Years (yrs). (2009) (5)
- Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens (2016) (5)
- Development of TP53 mutations over the course of therapy for acute myeloid leukemia (2021) (5)
- A phase I dose-escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. (2009) (5)
- Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia (2020) (5)
- Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis (2021) (5)
- Proposal for a new risk model in myelodysplastic syndrome (MDS) that accounts for events not considered in the original International Prognostic Scoring System (IPSS) (2008) (5)
- Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia (2019) (5)
- Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant (2021) (5)
- A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML) (2021) (5)
- MRD in HCL: does it matter? (2018) (5)
- SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia. (2007) (5)
- Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience (2018) (5)
- Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial. (2012) (5)
- Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure (2014) (5)
- A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. (2007) (5)
- Memory Impairment in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Treated with Dasatinib Tyrosine Kinase Inhibitor (TKI) Therapy (2011) (5)
- Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS) (2008) (5)
- Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid. (2009) (5)
- In Vivo Response to Sequential Tyrosine Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) Modeled Based on In Vitro Properties of Particular BCR-ABL Kinase Domain (KD) Mutations. (2007) (5)
- Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis (2020) (5)
- A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2021) (5)
- 10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply. (2019) (5)
- Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study (2016) (5)
- Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations (2014) (5)
- The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP) (2012) (5)
- Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) (2014) (5)
- Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents (2020) (5)
- CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). (2017) (5)
- Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia? (2014) (5)
- A mind map for managing minimal residual disease in acute myeloid leukemia. (2017) (5)
- Induction Therapy in Acute Myeloid Leukemia (2014) (5)
- Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy (2008) (5)
- A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium (2016) (5)
- Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (2010) (5)
- Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience (2020) (5)
- Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy (2009) (5)
- Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab (2022) (5)
- Purine analogue combinations for indolent lymphomas. (2006) (5)
- Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) (2018) (5)
- Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib. (2008) (5)
- The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. (2022) (5)
- Relapsed Acute Myeloid Leukemia: Need for Innovative Treatment Strategies to Improve Outcome. (2015) (5)
- Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia (2020) (5)
- Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification (2022) (5)
- An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia (2021) (5)
- Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial (2021) (5)
- Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL. (2005) (5)
- A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2012) (5)
- Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis (2016) (5)
- Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia – a distinct subtype with favorable prognosis (2020) (5)
- Inotuzumab Ozogamicin (IO) Is An Effective Salvage Therapy That Allows for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Remission in Patients with Advanced Acute Lymphoblastic Leukemia (ALL) (2011) (5)
- Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens. (2008) (5)
- Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) and myelodysplastic syndrome with ring sideroblasts (MDS‐RS) (2021) (5)
- VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia (2012) (5)
- Emerging Molecular and Immune Therapies in Acute Myeloid Leukemia (2017) (5)
- Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial (2016) (5)
- Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies (2017) (5)
- Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab (2020) (5)
- Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2011) (4)
- Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF. (2006) (4)
- The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. (2006) (4)
- Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis (2022) (4)
- Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL) (2013) (4)
- Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies. (2016) (4)
- The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2019) (4)
- Resistance to targeted therapies: delving into FLT3 and IDH (2022) (4)
- The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia (2020) (4)
- Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome (2015) (4)
- Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes (2020) (4)
- Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop (2011) (4)
- Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML) (2014) (4)
- Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD) (2019) (4)
- Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia (2019) (4)
- Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials (2016) (4)
- Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations (2020) (4)
- Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML) (2014) (4)
- Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse (2021) (4)
- Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (2013) (4)
- Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia (2018) (4)
- Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML): Abstract: CI‐026 (2017) (4)
- Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML) (2014) (4)
- Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML (2022) (4)
- Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experience (2021) (4)
- Estimated Glomerular Filtration Rate Changes In Patients (Pts) With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors (TKI) (2013) (4)
- TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia (2020) (4)
- A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia (2022) (4)
- Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). (2010) (4)
- Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2020) (4)
- A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML) (2016) (4)
- Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML). (2006) (4)
- Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP). (2005) (4)
- Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (2016) (4)
- A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). (2009) (4)
- Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC) (2010) (4)
- Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. (2017) (4)
- Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2013) (4)
- A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2021) (4)
- Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation. (2012) (4)
- Resource Utilization and Perceptions of Major Molecular Response In Chronic Myeloid Leukemia (CML): Results of a Delphi Panel Study. (2010) (4)
- Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System (2013) (4)
- Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. (2013) (4)
- Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia (AML). (2009) (4)
- Targeting acute myeloid leukemia with TP53-independent vosaroxin. (2017) (4)
- Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis (2018) (4)
- Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) (2016) (4)
- A Prognostic Model of Therapy-Related Myelodysplastic syndrome . (2009) (4)
- Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia (2021) (4)
- Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia (2013) (4)
- Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL) (2012) (4)
- Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. (2014) (4)
- Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts (2019) (4)
- Trial in Progress: A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia (2017) (4)
- Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. (2012) (4)
- Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP), (2011) (4)
- Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). (2021) (4)
- Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase (2016) (4)
- Management of Chronic Myeloid Leukemia (CML) during Pregnancy Among Patients (pts) Treated with a Tyrosine Kinase Inhibitor (TKI): A Single-Center Experience (2017) (4)
- Prophylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL) (2004) (4)
- Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study (2015) (4)
- Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (4)
- Adolescent and Young Adult Patients Treated with Modified Augmented Berlin-Frankfurt-Muenster Therapy (2010) (4)
- Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment (2022) (4)
- Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML) (2013) (4)
- Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial (2015) (4)
- Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation (2016) (4)
- Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS) (2019) (4)
- Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship (2017) (4)
- Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration (2021) (4)
- A phase I study with CP-4055 in patients with hematologic malignancies (2008) (4)
- Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML). (2018) (4)
- High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy (2016) (4)
- Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia (2016) (4)
- Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation (2012) (4)
- A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia (2017) (4)
- Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. (2013) (4)
- Acute Myeloid Leukemia as a Model for Cancer Therapy (2012) (3)
- Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs) (2012) (3)
- Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107. (2006) (3)
- A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib (2019) (3)
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia (2011) (3)
- A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). (2022) (3)
- CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia (2022) (3)
- Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia (2015) (3)
- A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy (2019) (3)
- Cause of death in patients with lower-risk myelodysplastic syndrome (MDS) (2008) (3)
- Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2021) (3)
- Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. (2018) (3)
- Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone (Augmented Hyper-CVAD) Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). (2007) (3)
- Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure (2020) (3)
- Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. (2007) (3)
- Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia (2020) (3)
- TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. (2018) (3)
- A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation (2021) (3)
- A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations (2013) (3)
- Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+ acute lymphoblastic leukemia. (2017) (3)
- A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). (2022) (3)
- Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). (2022) (3)
- Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. (2005) (3)
- Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics (2020) (3)
- Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years (2013) (3)
- Clinical relevance of mutations in patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms with normal karyotype. (2017) (3)
- Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy (2013) (3)
- A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. (2014) (3)
- Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification. (2022) (3)
- Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial (2020) (3)
- Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results (2023) (3)
- Response rates in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutation using 5-azacitadine plus sorafenib. (2012) (3)
- Count Recovery in AML Patients Achieving a Complete Response. (2009) (3)
- Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia (2016) (3)
- Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (2012) (3)
- Spontaneous Hematologic and Cytogenetic Remission in a Case of Acute Myelogenous Leukemia with Inversion 16 (2007) (3)
- Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study (2022) (3)
- Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis (2019) (3)
- Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison. (2013) (3)
- Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens (2019) (3)
- Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy (2016) (3)
- Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia (2015) (3)
- Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs) (2019) (3)
- A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy (2022) (3)
- The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial (2017) (3)
- Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. (2021) (3)
- Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL) (2008) (3)
- Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial (2020) (3)
- Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study (2018) (3)
- Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission. (2007) (3)
- Identifying effective drug combinations for patients with acute myeloid leukemia (2020) (3)
- Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution (2013) (3)
- t(9;22) as secondary alteration in core‐binding factor de novo acute myeloid leukemia (2015) (3)
- Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes (2022) (3)
- Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia. (2021) (3)
- Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). (2007) (3)
- BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center (2013) (3)
- Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC). (2020) (3)
- Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP), (2011) (3)
- Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts (2012) (3)
- Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy (2019) (3)
- Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission (2013) (3)
- Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Versus Conventional Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Attaining Complete Remission (CR1) Post Induction Chemotherapy: a Retrospective Case Control Study. (2008) (3)
- Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection (2011) (3)
- Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2014) (3)
- Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML (2021) (3)
- Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data (2018) (3)
- Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). (2019) (3)
- Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome (2013) (3)
- Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission (2020) (3)
- Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission (2018) (3)
- Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms (2012) (3)
- Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. (1999) (3)
- Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia (2018) (3)
- Association between bariatric surgery and outcomes in chronic myeloid leukemia. (2023) (3)
- Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) (2011) (3)
- Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2016) (3)
- Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance (2021) (3)
- Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance (2018) (3)
- Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? (2016) (3)
- Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia (2020) (3)
- Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia (2022) (3)
- Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL). (2009) (3)
- Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI) (2015) (3)
- Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia (2022) (3)
- Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2018) (3)
- Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS) (2021) (3)
- Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML (2017) (2)
- Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL) (2014) (2)
- Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2019) (2)
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response (2019) (2)
- Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher (2022) (2)
- Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies. (2007) (2)
- Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements (2014) (2)
- Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients (2022) (2)
- Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia. (2012) (2)
- Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML (2021) (2)
- Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents (2021) (2)
- A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia (2021) (2)
- Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia (2014) (2)
- Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML. (2020) (2)
- Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3) (2020) (2)
- Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) (2012) (2)
- New treatments and strategies in acute myeloid leukemia. (2011) (2)
- Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission. (2022) (2)
- Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes (2019) (2)
- Clinical, pharmacokinetic (PK), and pharmacodynamic findings from a phase I trial of an Eg5 inhibitor (AZD4877) in patients with refractory acute myeloid leukemia (AML). (2016) (2)
- Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials (2022) (2)
- Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis (2008) (2)
- A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations (2022) (2)
- Development of a distributed international patient data registry for hairy cell leukemia (2022) (2)
- A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (2017) (2)
- Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib (2020) (2)
- Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups (2014) (2)
- Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience (2012) (2)
- Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C (2012) (2)
- Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score. (2009) (2)
- Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience (2013) (2)
- Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy (2019) (2)
- Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia (2012) (2)
- Clinical value of event-free survival in acute myeloid leukemia. (2020) (2)
- An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial. (2015) (2)
- Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia (2013) (2)
- Response and Outcomes of Third-Line Tyrosine Kinase Inhibitor Therapy on Patients with Chronic Phase Chronic Myeloid Leukemia (2017) (2)
- Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia (2015) (2)
- Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab (2015) (2)
- Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy (2019) (2)
- Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib (2018) (2)
- The Role of Leukemia Inhibitory Factor in Cancer and Cancer Metastasis (2001) (2)
- Alemtuzumab in T-cell large granular lymphocyte leukaemia. (2016) (2)
- Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation (2013) (2)
- Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities (2015) (2)
- A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies. (2007) (2)
- Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents (2021) (2)
- Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). (2012) (2)
- Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma (2016) (2)
- Patients with Chronic Myeloid Leukemia with Variant Philadelphia Chromosome (Ph) Translocations Have a Similar Outcome as Those with Classic Ph When Treated with Imatinib or 2nd Generation TKI (2008) (2)
- Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR) (2011) (2)
- Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML (2013) (2)
- Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies. (2007) (2)
- Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL). (2016) (2)
- Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. (2020) (2)
- Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (2010) (2)
- AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial. (2022) (2)
- AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series. (2012) (2)
- A Phase I/II Trial of Combination of PKC412 and 5-azacytidine (AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2013) (2)
- Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure. (2012) (2)
- Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents (2020) (2)
- Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab (2018) (2)
- North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. (2022) (2)
- S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY (2022) (2)
- Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines. (2009) (2)
- CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US (2016) (2)
- Enhancing cytotoxicity of immunotoxins in AML. (2016) (2)
- A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia (2007) (2)
- 61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020 (2020) (2)
- Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL) (2015) (2)
- A Pilot Trial of Imatinib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic Phase (BP). (2005) (2)
- Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience (2016) (2)
- Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). (2018) (2)
- Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA). (2021) (2)
- S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY. (2019) (2)
- Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine (2021) (2)
- Preliminary Clinical, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of the Safety Run-In Part of a Phase II Trial of Orally Available MEK-Inhibitor MSC1936369 in Patients (Pts) with Advanced Hematological Malignancies (HM) (2010) (2)
- Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2021) (2)
- Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage. (2005) (2)
- Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission (2022) (2)
- Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin (2015) (2)
- Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia (2022) (2)
- Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia. (2009) (2)
- Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial (2017) (2)
- Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. (2017) (2)
- Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO (2019) (2)
- Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission (2021) (2)
- P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA (2022) (2)
- 947OCOMPARISON OF EFFICACY AND SAFETY OF 5-DAY AND 10-DAY SCHEDULES OF SGI-110, A NOVEL SUBCUTANEOUS (SC) HYPOMETHYLATING AGENT (HMA), IN THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML). (2014) (2)
- Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics (2014) (2)
- Modern treatment programs for adults with acute lymphoblastic leukemia (2007) (2)
- Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation (2020) (2)
- Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience (2018) (2)
- An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS (2019) (2)
- Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML) (2016) (2)
- A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML. (2018) (2)
- Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy (2008) (2)
- GR SNP helps transform myelofibrosis. (2012) (2)
- Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy. (2022) (2)
- Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation. (2005) (2)
- Novel treatments in acute myeloid leukemia. (2011) (2)
- Impact of variant allele frequency of mutant PTPN11 in AML: Single institution experience of 122 patients. (2018) (2)
- Design Of a Phase 1/2 Study Of Moxetumomab Pasudotox In Adult Patients With Relapsed and/Or Refractory Acute Lymphoblastic Leukemia (ALL) (2013) (2)
- Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase CML) (2016) (2)
- Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia (2017) (2)
- Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia (2020) (2)
- valproic acid in patients with leukemia -deoxycytidine with ' Phase 1/2 study of the combination of 5-aza-2 (2013) (2)
- Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice. (2018) (2)
- Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT (2018) (2)
- Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy (2012) (2)
- Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement (2019) (2)
- Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups (2021) (2)
- SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial (2021) (2)
- Contemporary outcomes for adults with AML requiring ICU admission. (2021) (2)
- Preclinical and early clinical study of forodesine hydrochloride (FH) in chronic lymphocytic leukemia (CLL). (2006) (2)
- Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant (2022) (2)
- Response Kinetics and Factors Predicting Survival Among Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) (2017) (2)
- Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy (2013) (2)
- Alemtuzumab (2005) (2)
- Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP). (2019) (2)
- Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy (2019) (2)
- Abstract B22: Genome-wide methylation analysis reveals an independently validated CpG island methylator phenotype associated with favorable prognosis in acute myeloid leukemia. (2015) (2)
- Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. (2017) (2)
- Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes (2019) (2)
- A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission (2021) (2)
- Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL) (2010) (2)
- Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. (2022) (2)
- Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML) (2021) (2)
- The potential role of Bi-specific antibodies in acute myeloid leukemia. (2020) (2)
- Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and Cytarabine (2017) (2)
- Is there a standard induction regimen for patients with AML? (2013) (2)
- Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia. (2019) (2)
- Incorporating Tyrosine Kinase Inhibitors into Treatment Regimens for AML and ALL: Is There a Right or Wrong Way? (2014) (2)
- Prognostic impact of trisomy 8 cytogenetic abnormality in acute myelogenous leukemia: Analysis of a large cohort (N=2187) of newly diagnosed patients. (2013) (2)
- FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden (2021) (2)
- P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL) (2022) (2)
- Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia. (2007) (2)
- Time to response and survival in hypomethylating agent-treated acute myeloid leukemia (2018) (2)
- Th1/17 Cells Are Expanded in Bronchial Alveolar Lavage (BAL) Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis (2017) (2)
- A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials (2016) (2)
- Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML. (2017) (2)
- Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. (2013) (2)
- Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. (2017) (2)
- Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. (2014) (2)
- Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome (2017) (1)
- Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML). (2009) (1)
- Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies (2016) (1)
- Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype (2020) (1)
- Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS) (2010) (1)
- Prognostic significance of hyperdiploidy in adult acute myeloid leukemia (2018) (1)
- Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study). (2008) (1)
- Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL) (2018) (1)
- Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study (2014) (1)
- NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (2021) (1)
- Impact of RAS Mutations In Myelodysplastic Syndrome (MDS) (2010) (1)
- Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia (2016) (1)
- P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (1)
- The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors (2021) (1)
- Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia (2023) (1)
- Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy (2016) (1)
- Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia (2020) (1)
- Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. (2011) (1)
- Molecular Insights in Patient Care Identification of a Novel Fusion Gene , IRF 2 BP 2-RARA , in Acute Promyelocytic Leukemia (2015) (1)
- Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission (2022) (1)
- TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia (2020) (1)
- Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts (2018) (1)
- IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. (2019) (1)
- Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome (2016) (1)
- An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML) (2015) (1)
- Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories (2020) (1)
- Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression (2020) (1)
- AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). (2022) (1)
- Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax (2021) (1)
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML): Abstract: AML‐025 (2017) (1)
- Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL). (2007) (1)
- Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant (2010) (1)
- Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia (2012) (1)
- Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. (2014) (1)
- First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia (2019) (1)
- The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) (2015) (1)
- FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations, (2011) (1)
- STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes (2016) (1)
- Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients (2018) (1)
- Clinical Significance of Dose Reductions of Dasatanib and Nilotinib When Used As Frontline Therapy for Chronic Phase -Chronic Myeloid Leukemia (CML-CP) Does Not Affect Outcome, (2011) (1)
- Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups (2020) (1)
- A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia (2022) (1)
- Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML) (2012) (1)
- Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells (2010) (1)
- Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis (2019) (1)
- Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (2014) (1)
- Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia (2022) (1)
- Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (2012) (1)
- Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (2016) (1)
- Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience (2011) (1)
- Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL) (2016) (1)
- Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC (2015) (1)
- Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series (2020) (1)
- Reply to Evaluation of PML Immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia (2011) (1)
- Phase Ii trial of 5-fluorouracil, folinic acid and recombinant α-2a-interferon in patients with advanced colorectal cancer (1999) (1)
- Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. (2010) (1)
- A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (2014) (1)
- Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia (2020) (1)
- Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML) (2011) (1)
- A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (2021) (1)
- Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type (2016) (1)
- OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) (2021) (1)
- Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia (2017) (1)
- Inotuzumab ozogamicin in combination with mini-hyper-CVD as salvage therapy for patients with relapsed/refractory acute lymphoblastic leukemia (2015) (1)
- Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML (2021) (1)
- Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML). (2012) (1)
- Cytokines in the treatment of acute leukemias. (2005) (1)
- The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution (2012) (1)
- Persistence of Cytogenetic Abnormalities at Complete Remission Is Not Prognostic for Relapse-Free or Overall Survival in Adult Patients with Acute Lymphoblastic Leukemia (2015) (1)
- A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations (2021) (1)
- Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML) (2016) (1)
- Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial (2015) (1)
- Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). (2011) (1)
- Myeloid Sarcoma of the Orbit and Ocular Adnexae (2012) (1)
- Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors (2018) (1)
- Oral Abstract: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia (2021) (1)
- The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency (2022) (1)
- Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation (2014) (1)
- MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS) (2021) (1)
- A New Nonrandom Chromosomal Translocation of Clonal Evolution in Chronic Myeloid Leukemia (2001) (1)
- Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML) (2010) (1)
- Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). (2017) (1)
- CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial. (2020) (1)
- Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade (2017) (1)
- Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS) (2018) (1)
- Biological and Clinical Features of Trisomy 21 Acute Myeloid Leukemia (2013) (1)
- Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (2016) (1)
- Characteristics, Outcomes and Treatment of Patients with T-Cell Prolymphocytic Leukemia (T-PLL) - Single-Center Experience (2016) (1)
- AML-186: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial (2020) (1)
- P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML (2022) (1)
- Development of Forodesine Hydrochloride (FH), an Inhibitor of Purine Nucleoside Phosphorylase, for Patients with Chronic Lymphocytic Leukemia (CLL). (2005) (1)
- The Role of Acute Myeloid Leukemia Minimal Residual Disease in Regulatory Decision-making-Reply. (2021) (1)
- Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial (2021) (1)
- Genomic Landscape of Mixed Phenotype Acute Leukemia (MPAL) (2017) (1)
- Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies. (2006) (1)
- Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center (2010) (1)
- Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia (2022) (1)
- Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction (2010) (1)
- Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux) (2013) (1)
- Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) (2020) (1)
- A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia (2021) (1)
- Analysis of Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Acute Myeloid Leukemia (2020) (1)
- CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (1)
- Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML (2021) (1)
- Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens (2016) (1)
- Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality (2017) (1)
- Flt3 in aml (2015) (1)
- Survival Outcomes in Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-than-Complete Response After First Salvage Therapy (2014) (1)
- Management of Relapsed/Refractory Acute Myeloid Leukemia (2020) (1)
- Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy (2012) (1)
- Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia (2015) (1)
- Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm) (2019) (1)
- Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort (2020) (1)
- Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure (2015) (1)
- Genomic landscape of adult mixed phenotype acute leukemia (MPAL). (2017) (1)
- Hairy cell leukemia. (2009) (1)
- Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C). (2005) (1)
- Analysis of Outcomes In Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia (CML) Treated with Upfront Tyrosine Kinase Inhibitors (TKI) (2010) (1)
- SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies (2013) (1)
- Clinical significance of MYC expression in acute myeloid leukemia. (2014) (1)
- ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. (2022) (1)
- Imatinib Maintenance Following Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Philadelphia Chromosome Positive (PH+) Acute Lymphoblastic Leukemia (ALL) (2010) (1)
- Urgent Cytoreductive Chemotherapy for Newly Diagnosed Patients with AML Is Safe and Feasible and Facilitates Enrollment on Investigational Clinical Trials (2020) (1)
- Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (2022) (1)
- Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation. (2005) (1)
- Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy (2010) (1)
- Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML). (2013) (1)
- Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients (2022) (1)
- Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC. (2012) (1)
- Retrospective analysis of effects of dose modification and myelosuppression on response to decitabine and overall survival in patients with myelodysplastic syndromes. (2011) (1)
- Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial (2017) (1)
- Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy. (2019) (1)
- Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment (2016) (1)
- Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement (2013) (1)
- The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent. (2009) (1)
- Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase. (2009) (1)
- Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial (2017) (1)
- Current and emerging treatments for acute promyelocytic leukemia (2019) (1)
- Validation of a DNA Methylation Signature of Favorable Prognosis in Newly Diagnosed Acute Myeloid Leukemia. (2009) (1)
- PB1722 IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN (2019) (1)
- ALL-315: Outcome of Adults with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (2020) (1)
- Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia (2010) (1)
- Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM) Therapy (2011) (1)
- Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemia (2016) (1)
- Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial (2020) (1)
- Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. (2008) (1)
- Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up (2018) (1)
- The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia (2018) (1)
- Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia, (2011) (1)
- Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a hyperdiploid karyotype. (2014) (1)
- DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML (2013) (1)
- Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics (2021) (1)
- Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse (2018) (1)
- Updated Results from Phase 2 Study of Guadecitabine for Patients with Untreated INT-2/High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (2017) (1)
- Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP). (2016) (1)
- P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML (2022) (1)
- Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses (2014) (1)
- Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation (2015) (1)
- Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease (2018) (1)
- Mixed Phenotype Acute Leukemia: Patient Outcomes According to the WHO 2008 Classification (2013) (1)
- Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS) (2019) (1)
- CREB/ATF Family Protein Expression States in AML: Active CREB1, but Not ATF Is an Adverse Prognostic Factor (2014) (1)
- Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies (2020) (1)
- Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial (2021) (1)
- Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study (2015) (1)
- Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia (2022) (1)
- Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (2011) (1)
- A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy (2022) (1)
- Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy. (2009) (1)
- Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (2014) (1)
- MYC protein expression as prognostic in acute myeloid leukemia. (2016) (1)
- Is There a Clinical Benefit for Less Than a Complete Cytogenetic Response (CCyR) for Patients (Pts) with Chornic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors (TKI) as Second or Third Line Therapy (2010) (1)
- "It's effective therapy, stupid!". (2013) (1)
- Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. (2008) (1)
- Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine (2020) (1)
- Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial. (2022) (1)
- Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure (2015) (1)
- Updated definition of cure in adult patients with non-APL acute myeloid leukemia (2015) (1)
- Phase 1 study of anti-CD 33 immunotoxin HUM-195 / rGEL in patients with advanced myeloid malignancies (2012) (1)
- untreated patients with chronic lymphocytic leukemia Prognostic nomogram and index for overall survival in previously (2013) (1)
- Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade (2014) (1)
- Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era (2012) (1)
- PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML) (2019) (1)
- Expression of Apoptosis Repressor with Caspase Recruitment Domain (ARC), An Antiapoptotic Protein, Is Strongly Prognostic in Acute Myeloid Leukemia (AML). (2009) (1)
- Horse versus rabbit antithymocyte globulin in aplastic anemia. (2011) (1)
- Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies. (2022) (1)
- Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction. (2008) (1)
- A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP). (2005) (1)
- Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib (2020) (1)
- Effective Very Long Term (6+ Years) Lenalidomide Therapy for Myelofibrosis (2014) (1)
- Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy (2020) (1)
- Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) (2013) (1)
- Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors (2021) (0)
- AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)- Based Regimen. (2022) (0)
- Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML) (2013) (0)
- Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia (2022) (0)
- Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) in Adults: A High-Risk Subtype (2015) (0)
- Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience (2010) (0)
- Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure (2022) (0)
- Expression and Prognostic Impact of Candidate Suppressor Sequence-Specific Single-Stranded DNA Binding Protein (SSBP2) in AML Using Reverse Phase Proteins Arrays (RPPA). (2007) (0)
- A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up (2022) (0)
- Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy (2022) (0)
- High Prevalence of FLT3 - ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Central Nervous System (CNS) Relapse. (2009) (0)
- A Distributed International Patient Data Registry for Hairy Cell Leukemia (2016) (0)
- Treatment of acute myeloid leukemia in older adults: time to reflect? (2006) (0)
- Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial (2023) (0)
- Propensity score analysis: Frontline therapy with high-dose (HD) imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. (2015) (0)
- Targeted Therapies for AML (2018) (0)
- Fatigue and Physical Activity Before and Immediately After Stem Cell Transplantation (2011) (0)
- Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2018) (0)
- Effect of hematologic improvement (HI) on survival in patients (pts) given targeted therapy (TT) as initial treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) (2007) (0)
- Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic Stem Cell Transplantation. (2023) (0)
- PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. (2023) (0)
- Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia (2021) (0)
- Treating adults with acute lymphoblastic leukemia: it is time to grow up (2013) (0)
- Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). (2009) (0)
- A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). (2009) (0)
- Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse. (2017) (0)
- Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies. (2006) (0)
- Characteristics and outcomes of myelodysplastic syndrome (MDS) with chromosome (chr)3q abnormalities. (2018) (0)
- Prognostic Impact of Mutations in Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with Normal Karyotype (2017) (0)
- Harnessing the Immune System for Treating AML (2019) (0)
- Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens (2018) (0)
- Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (2016) (0)
- Prognostic significance of blood counts at time of complete remission in acute myeloid leukemia (2008) (0)
- Survival benefit with imatinib mesylate versus interferon- (cid:1) –based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia (2006) (0)
- Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2019) (0)
- P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2022) (0)
- Prognostic Impact of Kinase Mutations and Minimal Residual Disease in Core-Binding Factor Leukemia (2015) (0)
- P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB (2022) (0)
- Quantitative Assessment of Translocation Transcript Ratio Predicts for Relapse Free Survival Among Patients with Core Binding Factor Acute Myeloid Leukemia (2014) (0)
- Higher Bone Marrow Lymphocyte Percentage 3 to 6 Month After Therapy with Hypercvad + Dasatinib Than That with Hypercvad + Imatinib or Hypercvad Alone In Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (2010) (0)
- Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL) (2016) (0)
- Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center (2012) (0)
- Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin (2015) (0)
- Defining the landscape of resistance mutations in the context of modern treatment protocols for acute promyelocytic leukaemia (2009) (0)
- Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes (2017) (0)
- 510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation (2011) (0)
- Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? (2019) (0)
- Effect of vorinostat use on survival in patients with acute myeloid leukemia (AML) with FLT3 ITD mutations. (2015) (0)
- Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL) (2015) (0)
- Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL) (2015) (0)
- Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase (2018) (0)
- Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma (2016) (0)
- Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens (2012) (0)
- Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS) (2022) (0)
- A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs) (2019) (0)
- Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy (2022) (0)
- The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study (2022) (0)
- Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia (2023) (0)
- The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades (2023) (0)
- Persistence of Preleukemic Clonal Hematopoiesis after Chemotherapy is Associated with Poor Prognosis in Patients with High Risk MDS and AML (2017) (0)
- Effect of FLT3 and RAS Mutations on Protein Expression Patterns In Cases of Acute Myelogenous Leukemia (AML) with NPM1 Mutations (2010) (0)
- ALL-326: Low Incidence of Central Nervous System (CNS) Relapse with Hyper-CVAD-R Regimen in Adults with Burkitt Lymphoma/Leukemia (BL) and High-Grade B-Cell Lymphoma (HGBCL) (2020) (0)
- Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience (2009) (0)
- Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimens (2022) (0)
- Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis (2010) (0)
- The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (2019) (0)
- P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (0)
- Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI) (2017) (0)
- Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts. (2018) (0)
- Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study (2022) (0)
- Outcomes Of Repeated Administration Of Rasburicase In Recurrent Cycles For Patients With Leukemia (2013) (0)
- receiving alemtuzumab-based therapy Valganciclovir prevents cytomegalovirus reactivation in patients (2013) (0)
- Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease? (2018) (0)
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia (2021) (0)
- PF281 CLI24–001: FIRST IN HUMAN STUDY OF SEL24/MEN1703, AN ORAL DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (2019) (0)
- Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome (2022) (0)
- Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis (2019) (0)
- Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy (2022) (0)
- How We Treat Patients with Relapsed/Refractory AML (2015) (0)
- CHARACTERIZATION OF PATIENTS WITH RELAPSED OR REFRACTORY AML IN CONTINUED FOLLOW-UP AFTER TREATMENT WITH VOSAROXIN/CYTARABINE VS PLACEBO/CYTARABINE IN THE VALOR TRIAL (2016) (0)
- **504 Detection of Cytogenetic Abnormalities Associated with Outcome Differences in Acute Myeloid Leukemia Using Array-Based Comparative Genomic Hybridization (aCGH) Analysis (2011) (0)
- 1076: Sepsis in Acute Myeloid Leukemia (2013) (0)
- University of Birmingham Evaluating measurable residual disease in acute myeloid leukemia (2018) (0)
- Maintenance therapy in acute myeloid leukemia: advances and controversies. (2023) (0)
- Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML) (2008) (0)
- Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. (2023) (0)
- Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML) (2013) (0)
- The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms (2022) (0)
- AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. (2022) (0)
- Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome (2018) (0)
- Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy (2022) (0)
- Antibody-based targeted therapies. (2020) (0)
- Optimized Voronoi compartment determination using machine-learning to identify prognostic groups of patients based on cellular behavior in treated AML (2015) (0)
- Poster: AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia (2022) (0)
- Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL). (2008) (0)
- Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL) (2014) (0)
- Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI). (2016) (0)
- EXABS-149-AML Is All Oral Therapy of AML a Reality for the Future? (2022) (0)
- Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia (2018) (0)
- Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study (2022) (0)
- Effect of FMS-Like Tyrosine Kinase-3 Mutations on Prognosis in Acute Myeloid Leukemia: A Single Institution Experience between 2000 and 2007. (2007) (0)
- Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen (2016) (0)
- Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study (2015) (0)
- Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients (2016) (0)
- Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML) (2013) (0)
- RAS mutation acquisition at transformation from myelodysplastic syndrome to acute myeloid leukemia to predict poor outcome. (2015) (0)
- Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia (2015) (0)
- Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up (2014) (0)
- Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia (2022) (0)
- Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO). (2010) (0)
- Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase (2014) (0)
- CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia. (2019) (0)
- Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes (2018) (0)
- Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP) (2014) (0)
- Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs (2018) (0)
- P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2022) (0)
- A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms (2022) (0)
- Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status (2016) (0)
- Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors). (2012) (0)
- Novel treatment options for acute myelocytic leukemia (2013) (0)
- A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL (2016) (0)
- A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes (2022) (0)
- Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib (2019) (0)
- A Phase Ib Pilot Study of Itacitinib Combined with Alemtuzumab in Patients with T-Cell Prolymphocytic Leukemia (T-PLL) (2021) (0)
- Outcomes of Patients with Chronic Phase CML Who Discontinued Ponatinib in the Frontline Setting (2015) (0)
- Phase I Study of Bendamustine in Refractory Leukemia. (2009) (0)
- MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes (2014) (0)
- Poster: CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia (2022) (0)
- MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study: AML‐103 (2018) (0)
- Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies (2022) (0)
- positive leukemias - Philadelphia chromosome secondary genetic changes in determining the phenotype of BCR-ABL fusion transcript types and levels and their interaction with (2013) (0)
- Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia (2012) (0)
- Impact of the type of first-cancer therapy in therapy-related myelodysplastic syndromes outcomes. (2017) (0)
- Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes (2018) (0)
- Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements (2023) (0)
- The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right? (2017) (0)
- PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS) (2019) (0)
- Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study (2022) (0)
- Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia (2015) (0)
- Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL) (2020) (0)
- Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (2011) (0)
- Novel Chemotherapeutics in AML (2017) (0)
- ALL-346 Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients. (2022) (0)
- Abstract 5033: Clonal origin of therapy-related myeloid neoplasms (2016) (0)
- P-269: COVALENT-101: a Phase 1 study of BMF-219, a novel oral covalent menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma (2022) (0)
- myeloid leukemia (AML) in patients 50 years of age or older Clofarabine and cytarabine combination as induction therapy for acute (2013) (0)
- Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals (2022) (0)
- AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant (2020) (0)
- Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia (2020) (0)
- ALL-216: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy (2020) (0)
- Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia (2022) (0)
- Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL) (2017) (0)
- Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse (2015) (0)
- CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. (2022) (0)
- Oral Abstract: ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination with Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2022) (0)
- Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy (2011) (0)
- Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). (2016) (0)
- Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD). (2018) (0)
- Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms (2016) (0)
- Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes (2020) (0)
- Abstract 2725: The single-cell atlas of driver mutations in acute myeloid leukemia (2019) (0)
- chronic myeloid leukemia in accelerated or blast phase inhibitors is associated with a poor prognosis among patients with major cytogenetic response with second-generation tyrosine kinase Failure to achieve a complete hematologic response at the time of a (2013) (0)
- Poster: MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes (2022) (0)
- Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure (2012) (0)
- DNMT3A mutations exert a dominant adverse effect in De novo acute myeloid leukemia with concurrent FLT3 and NPM1 mutations (2015) (0)
- AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML), (2011) (0)
- P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN (2022) (0)
- Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy (2018) (0)
- RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia (2022) (0)
- AML-318: Predictors of Outcomes in AML with MLL Rearrangement (2020) (0)
- Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype (2022) (0)
- Recurrent Patterns Of Histone Methylation and Acetylation Regulating Protein Expression In Acute Myelogenous Leukemia (AML) (2013) (0)
- Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors (2016) (0)
- Prognostic Impact of Full Hematologic Recovery and Achievement of Measurable Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) After First Salvage Therapy (2019) (0)
- Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype (2019) (0)
- Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (2012) (0)
- P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY (2022) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years (2022) (0)
- Feasibility of hypomethylating therapy in patients with renal insufficiency. (2009) (0)
- Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy (2020) (0)
- Clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph-) emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are treated with tyrosine kinase (2017) (0)
- Incidence, Clinical Features and Outcome of Patients with Differentiation Syndrome in Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid (ATRA) Alone Versus ATRA Plus Idarubicin Versus ATRA Plus Arsenic Trioxide. (2009) (0)
- Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment (2022) (0)
- Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome (2019) (0)
- To the editor: Ventricular arrhythmias and sudden death in patients taking ibrutinib (2017) (0)
- Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia (2021) (0)
- Baseline Mutations Lack Impact on Clinical Outcomes and Molecular Response in Core Binding Factor Leukemia Treated with Highly Effective Regimen (2020) (0)
- Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation. (2018) (0)
- Mutant NPM1 is a Reliable Marker of Minimal Residual Leukemia in Patients with Acute Myeloid Leukemia (2013) (0)
- Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. (2009) (0)
- Exome analysis of treatment‐related AML after APL suggests secondary evolution (2018) (0)
- Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia (2018) (0)
- Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial (2022) (0)
- Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen (2012) (0)
- Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). (2012) (0)
- Allogeneic Hematopoietic Cell Transplant in Patients ≥60 Years of Age With First Relapsed or Refractory Acute Myeloid Leukemia After Treatment With Vosaroxin Plus Cytarabine vs Placebo Plus Cytarabine: Results From VALOR (2015) (0)
- Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis. (2007) (0)
- Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia (2022) (0)
- Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs) (2019) (0)
- Prognostic Index and Nomogram for Overall Survival (OS) of Adult Patients with Philadelphia-negative B-cell ALL (2016) (0)
- Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab (2022) (0)
- Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure (2008) (0)
- Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. (2023) (0)
- MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. (2022) (0)
- Characteristics and Outcomes of Malignancy‐Associated Hemophagocytic Lymphohistiocytosis (M‐HLH) in Adult Patients: A Single‐Center Experience: Abstract: IIC‐029 (2017) (0)
- Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study (2020) (0)
- Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21 (2012) (0)
- A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia (2013) (0)
- Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours (2023) (0)
- A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL (2017) (0)
- Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients (2016) (0)
- Therapy Related Cellular Changes as a Tool for Prognosis in AML (2014) (0)
- Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status (2016) (0)
- Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML) (2022) (0)
- Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study (2020) (0)
- Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (2017) (0)
- Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure (2015) (0)
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms (2019) (0)
- Characteristics and outcomes of patients with multiple myeloma (MM) who develop therapy (t)-related myelodysplastic syndrome (MDS), t-chronic myelomonocytic leukemia (CMML), or t-acute myeloid leukemia (AML) patients underwent high-dose chemotherapy and autologous hematopoietic stem cell (2015) (0)
- Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations. (2009) (0)
- Blinatumomab in B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease: Initial Results of a Phase II Trial (2017) (0)
- Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period. (2018) (0)
- Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). (2016) (0)
- Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML) (2014) (0)
- Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse (2011) (0)
- A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (2011) (0)
- Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2013) (0)
- Outcomes with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine as Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: Abstract: AML‐015 (2017) (0)
- Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor‐Induced Pneumonitis: Abstract: CI‐027 (2017) (0)
- Characteristics and outcomes of patients diagnosed with DNMT3A mutated acute myeloblastic leukemia. (2021) (0)
- Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience (2014) (0)
- Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis (2021) (0)
- P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (2022) (0)
- Long-Term Outcome of CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors in the Second Line: A Single Center Experience (2017) (0)
- Evaluation of the Gene Xpert DX System for Molecular Monitoring in CML (2012) (0)
- Survival Outcomes for Patients in the QUAZAR AML-001 Trial Who Received Subsequent Therapy for Acute Myeloid Leukemia (AML) after Discontinuing Oral Azacitidine or Placebo (2022) (0)
- A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (2022) (0)
- AML-310: Prognostic Value of CRh in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine (2021) (0)
- Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia (2011) (0)
- A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML) (2022) (0)
- Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2017) (0)
- Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2019) (0)
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy (2022) (0)
- Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents (2014) (0)
- Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib. (2007) (0)
- Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR (2013) (0)
- Outcomes with lower intensity therapy in TP53-mutated AML. (2017) (0)
- and T315I mutation following failure of imatinib mesylate therapy Characteristics and outcomes of patients with chronic myeloid leukemia (2013) (0)
- Myelodysplastic Syndromes and Acute Myeloid Leukemia with t(6;9)(p23;q34). (2007) (0)
- Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (2016) (0)
- The Time to Cytogenetic Response Determines Survival in CML Patients (Pts) Receiving Second-Line Tyrosine Kinase Inhibitors, and Allows Early Identification of Pts Destined To Fail Therapy. (2007) (0)
- Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age (2013) (0)
- Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival (2015) (0)
- A phase I/II trial of combination of PKC412 and 5-azacytidine (AZA) for the treatment of patients with refractory or relapsed (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). (2012) (0)
- P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE (2022) (0)
- P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS) (2022) (0)
- A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL (2016) (0)
- Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF) (2014) (0)
- Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial (2017) (0)
- leukemia higher risk myelodysplastic syndrome and chronic myelomonocytic Results of a randomized study of three schedules of low-dose decitabine in (2013) (0)
- Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (2016) (0)
- Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy (2011) (0)
- Acute Myeloid Leukemia Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia (2013) (0)
- Poster: MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes (2022) (0)
- Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia (2019) (0)
- Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy (2019) (0)
- Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen. (2007) (0)
- Approaching the Treatment of AML from a Biological Perspective (2007) (0)
- Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes (2010) (0)
- Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). (2023) (0)
- Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients (2013) (0)
- Acute myeloid leukemia: current progress and future directions (2021) (0)
- Investigational agents in myeloid disorders. (2004) (0)
- PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34) (2022) (0)
- Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2019) (0)
- Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients (2022) (0)
- Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia, (2011) (0)
- Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS), (2011) (0)
- Central nervous system relapse in adults with acute lymphoblastic leukemia. (2014) (0)
- Value of Immunohistochemistry-Based Direct Visualization for Localization, Lineage Determination and Monitoring of IDH1 p.R132H Mutant Clones in AML (2016) (0)
- A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS) (2012) (0)
- Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia? (2022) (0)
- A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. (2012) (0)
- Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis (2015) (0)
- Detection of Cytogenetic Abnormalities Associated with Outcome Differences in Acute Myeloid Leukemia Using Array-Based Comparative Genomic Hybridization (aCGH) Analysis. (2009) (0)
- Propensity score matched comparison of intermediate-intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age ≥ 60) with acute myeloid leukemia (AML). (2014) (0)
- PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY (2019) (0)
- Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML. (2017) (0)
- A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy (2014) (0)
- ASCO 2014: High prevalence of FLT-3 ITD mutations in patients (pts) with AML who present with CNS relapse. (2014) (0)
- Outcomes of patients with nucleoplasmin 1 (NPM1) mutated acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs). (2018) (0)
- Methylation in aml: Clinical applications (2015) (0)
- Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). (2007) (0)
- Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience (2014) (0)
- Comorbidity Scoring Using the Hematopoetic Cell Transplantation Comorbidity Index (HCTCI) Is Predictive of Early Death Rate and Event Free Survival (EFS) in Patients over 60 Years of Age Receiving Induction Therapy for Acute Myeloid Leukemia (AML). (2006) (0)
- The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both All–Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO). (2009) (0)
- HCL: insights into biology. (2011) (0)
- A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (2022) (0)
- Abstract 5302: Genome-wide methylation analysis reveals multiple epigenetic subtypes of acute myeloid leukemia (2015) (0)
- Report of a Phase1/2 Study of 5-Azacitidine and Cytarabine in Patients with Relapsed, Refractory Acute Myelogenous Leukemia. (2007) (0)
- Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic Syndromes (2020) (0)
- A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML (2014) (0)
- A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (2010) (0)
- Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML). (2010) (0)
- Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections (2018) (0)
- Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience (2023) (0)
- Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission (2022) (0)
- Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission (2015) (0)
- Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD (2015) (0)
- A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Abstract: AML‐024 (2017) (0)
- Abstract 4715: Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP) (2011) (0)
- COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). (2022) (0)
- P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (0)
- Acute Myeloid Leukemia S 60 New Treatments and Strategies in Acute Myeloid Leukemia (2011) (0)
- Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia, (2011) (0)
- P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL (2022) (0)
- AML-291: Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia (2021) (0)
- Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study. (2017) (0)
- Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL). (2009) (0)
- Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI Modalities (2016) (0)
- Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure. (2011) (0)
- AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia (2021) (0)
- Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors (2016) (0)
- Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An Inv(16)(p13.3;q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital – Washington University Pediatric Cancer Geno (2011) (0)
- Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond (2022) (0)
- Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia (2018) (0)
- Is Maintenance Therapy Necessary in AML (2021) (0)
- P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS (2022) (0)
- Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia (2018) (0)
- Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. (2020) (0)
- The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
- Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL. (2005) (0)
- Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen (2018) (0)
- Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO). (2012) (0)
- Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia (2015) (0)
- Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. (2012) (0)
- A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia (2021) (0)
- Inotuzumab ozogamicin (INO) in combination with mini-hyper-CVD as frontline therapy for older patients (≥60 years) with acute lymphoblastic leukemia (ALL) (2015) (0)
- Poster: ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2022) (0)
- Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis (2020) (0)
- Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia (2020) (0)
- Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome. (2008) (0)
- P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (2022) (0)
- Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials (2022) (0)
- Allogeneic hematopoietic cell transplant (HCT) in patients (pts) ≥ 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR. (2015) (0)
- Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
- Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy (2022) (0)
- Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML) (2022) (0)
- Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem? (2010) (0)
- Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System (2016) (0)
- Phase II study of thymoglobulin, cyclosporine and G-CSF for initial treatment of aplastic anemia and low risk myelodysplastic syndrome (2008) (0)
- Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma (2020) (0)
- Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens (2016) (0)
- Outcome of FLT3 ITD Mutated AML Patients Based on Different Treatment Strategies (2015) (0)
- Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase (2014) (0)
- Improved Acute Graft‐versus Host Disease (aGVHD) and Progression Free Survival with Post‐Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA‐4 or PD‐1 Blockade: Abstract: CI‐028 (2017) (0)
- MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. (2022) (0)
- Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia (2010) (0)
- Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Myeloid Leukemia (AML) (2020) (0)
- Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor (2016) (0)
- Vosaroxin in Combination With Cytarabine Provides a New Salvage Option for AML (2014) (0)
- Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) on Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) With Acute Promyelocytic Leukemia (APL) Treated With All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) (2013) (0)
- Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP) (2012) (0)
- Impact of Next-Generation Sequencing on Treatment Choices for Patients with Acute Myeloid Leukemia (2017) (0)
- Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update. (2009) (0)
- Expert insights into the contemporary management of older adults with acute myeloid leukemia. (2013) (0)
- Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase 3 QUAZAR AML-001 trial. (2023) (0)
- P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA (2022) (0)
- Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens (2022) (0)
- P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) (2022) (0)
- Poster: AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD) (2022) (0)
- Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach (2016) (0)
- Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen (2011) (0)
- Abstract A50: Distinguishing Mosaic Li Fraumeni Syndrome, Clonal Hematopoiesis and Incidental Myeloid Neoplasms in Patients with Solid Tumors with Pathogenic TP53 Mutations Identified by Germline Testing or Cell-Free Circulating DNA Sequencing (2023) (0)
- Dr. Elihu H. Estey (1946–2021) (2021) (0)
- Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis. (2007) (0)
- PS4-1 Phase II study of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia (2022) (0)
- Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful? (2019) (0)
- NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology (2017) (0)
- Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia. (2007) (0)
- Association of early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) with high response rates and long duration of response. (2018) (0)
- SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial (2020) (0)
- Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy (2021) (0)
- Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML (2015) (0)
- Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML). (2019) (0)
- Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome (2019) (0)
- Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). (2011) (0)
- Outcomes of patients (pts) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) with bone marrow necrosis (BMN) at initial diagnosis. (2014) (0)
- Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) (2018) (0)
- Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis (2013) (0)
- Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL) (2012) (0)
- HCVAD plus Imatinib or Dasatinib for Lymphoid Blastic Phase of Chronic Myeloid Leukemia (2013) (0)
- Clinical impact of dose intensity of initial tyrosine kinase inhibitor (TKI) therapy in accelerated-phase CML (CML-AP). (2012) (0)
- Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results (2022) (0)
- Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy (2021) (0)
- inhibitor modalities diagnosed chronic myeloid leukemia : results with four tyrosine kinase Early responses predict better outcomes in patients with newly (2013) (0)
- Correlation between peripheral blood and bone marrow samples for detection of PML-RARA fusion transcripts by quantitative PCR in patients with acute promyelocytic leukemia (2015) (0)
- Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens (2020) (0)
- Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials (2021) (0)
- Evolution of the AML Genome and Epigenome during IDH Inhibitor Therapy and their Association with Clinical Response and Resistance (2019) (0)
- Short Telomere Syndromes and Inherited Predisposition to Bone Marrow Diseases: The MDACC Experience (2022) (0)
- Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial (2012) (0)
- Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia (2018) (0)
- S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML (2019) (0)
- Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia. (2012) (0)
- The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) (2019) (0)
- Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML. (2018) (0)
- A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies (2022) (0)
- Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial (2015) (0)
- Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis (2012) (0)
- Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder (2011) (0)
- P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE (2022) (0)
- Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. (2012) (0)
- Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2016) (0)
- Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse (2020) (0)
- Comment on Poletto et al , page 3112 GR SNP helps transform myelofibrosis (0)
- Senior adult oncology: three cases of advanced cancer in patients of advanced age. (2012) (0)
- Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy (2019) (0)
- Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia (2021) (0)
- Is acute myeloid leukaemia maintenance therapy necessary? (2022) (0)
- AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. (2022) (0)
- Allogeneic Transplantation in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD positive AML Blood Marrow (2018) (0)
- CD56 as a predictor of central nervous system relapse in acute lymphoblastic leukemia (2000) (0)
- Deconvolution of Clonal Heterogeneity in Acute Myeloid Leukemia using Single-Cell DNA Sequencing (2019) (0)
- Running title: Sorafenib in hematologic malignancies (2010) (0)
- A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab (2020) (0)
- S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA (2019) (0)
- Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status (2013) (0)
- Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI) (2018) (0)
- Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial. (2022) (0)
- Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Stud (2020) (0)
- Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome (2016) (0)
- Impact of Cytogenetics on Clinical Outcome in Patients with First Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine Vs Placebo Plus Cytarabine: Results from VALOR (2015) (0)
- Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia (2019) (0)
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies: Abstract: AML‐016 (2017) (0)
- Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study (2016) (0)
- Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center (2011) (0)
- Long Term Effect of Decitabine (DAC) Dose Delay (DD) and Dose Reduction (DR) on Survival and Progression of Patients (pts) with Myelodysplastic Syndrome (MDS) (2013) (0)
- Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia (2022) (0)
- Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia (2020) (0)
- Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis (2020) (0)
- Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL (2016) (0)
- Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival (2015) (0)
- Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility (2012) (0)
- Phase 1 and Extension Study of Clofarabine plus Cyclophosphamide in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia ( ALL ) (2014) (0)
- Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)? (2015) (0)
- Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. (2018) (0)
- Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia (2012) (0)
- Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival. (2007) (0)
- Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib (2022) (0)
- P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) (2022) (0)
- Outcomes of Relapsed Core Binding Factor Acute Myeloid Leukemia: an MD Anderson Experience (2016) (0)
- PS1037 FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS (2019) (0)
- Fatigue, Physical Activity, Health Status, and Quality of Life in Stem Cell Transplant Patients (2011) (0)
- JAK2 Variants Associated with Secondary-AML from MPN (2017) (0)
- O4 The hematopoietic cell transplantation comorbidity index predicts outcomes in elderly patients with acute myeloid leukemia undergoing induction therapy: a single center experience of 177 patients (2006) (0)
- Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies (2020) (0)
- A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) (2012) (0)
- FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). (2012) (0)
- Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR) (2019) (0)
- Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL) (2016) (0)
- Adults with Acute Lymphoblastic Leukemia and T(1;19) Abnormality Have a Favorable Outcome with Hyper-CVAD Chemotherapy (2008) (0)
- P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS (2022) (0)
- Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. (2012) (0)
- Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications (2014) (0)
- Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years. (2008) (0)
- AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). (2022) (0)
- PF212 NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS (2019) (0)
- Philadelphia Chromosome -P ositive Acute Lymphoblastic Leukemia (2009) (0)
- Early Maintenance with Tyrosine Kinase Inhibitors Post Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Improves Survival in Ph+ Acute Lymphoblastic Leukemia (ALL) Patients (2017) (0)
- AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial. (2022) (0)
- Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality (2016) (0)
- AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. (2022) (0)
- Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR+) Populations In Patients With Myelodysplastic Syndrome (MDS) (2013) (0)
- Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy (2020) (0)
- Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities (2012) (0)
- Quantifying the Survival Benefit for Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia (2014) (0)
- Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy. (2015) (0)
- Impact of the Type of First-Cancer Therapy in Therapy-Related Myelodysplastic Syndromes Outcomes (2017) (0)
- Chemotherapy-free treatment of acute promyelocytic leukemia. (2015) (0)
- Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib (2015) (0)
- Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial (2022) (0)
- Ponatinib and Blinatumomab for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Phase 2 Trial (2022) (0)
- The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience (2015) (0)
- Final results of phase I and pharmacokinetic study of SJG-136 administered on a daily x 5 schedule. (2009) (0)
- European leukemia net (ELN) 2013 response categories: Impact on clinical outcomes across four frontline tyrosine kinase inhibitor (TKI) modalities in chronic phase CML. (2014) (0)
- Time to revise the revised-International Prognostic Scoring System? (2015) (0)
- An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS). (2009) (0)
- Dynamics of Measurable Disease at Remission Determines Survival in Patients (Pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL) (2017) (0)
- Ofatumumab in Combination with Hyper-CVAD Regimen as Frontline Treatment for Adults with CD-20 Positive Acute Lymphocytic Leukemia (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Farhad Ravandi?
Farhad Ravandi is affiliated with the following schools:
